Cargando…
2′-Fucosyllactose Ameliorates Inflammatory Bowel Disease by Modulating Gut Microbiota and Promoting MUC2 Expression
Gut microbiota dysbiosis, together with goblet cells dysfunction has been observed in ulcerative colitis cases. This study aims to evaluate the potential of 2′-fucosyllactose (2′-FL) supplementation in inhibiting intestinal inflammation through regulating gut microbiota, protecting goblet cells, and...
Autores principales: | Yao, Qianqian, Fan, Linlin, Zheng, Nan, Blecker, Christophe, Delcenserie, Véronique, Li, Huiying, Wang, Jiaqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892212/ https://www.ncbi.nlm.nih.gov/pubmed/35252301 http://dx.doi.org/10.3389/fnut.2022.822020 |
Ejemplares similares
-
The Milk Active Ingredient, 2′-Fucosyllactose, Inhibits Inflammation and Promotes MUC2 Secretion in LS174T Goblet Cells In Vitro
por: Yao, Qianqian, et al.
Publicado: (2023) -
2′-Fucosyllactose Remits Colitis-Induced Liver Oxygen Stress through the Gut–Liver–Metabolites Axis
por: Yao, Qianqian, et al.
Publicado: (2022) -
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease
por: Guo, Xue, et al.
Publicado: (2022) -
Apigenin remodels the gut microbiota to ameliorate ulcerative colitis
por: Fu, Rongrong, et al.
Publicado: (2022) -
Effects of addition of 2-fucosyllactose to infant formula on growth and specific pathways of utilization by Bifidobacterium in healthy term infants
por: Wallingford, John C., et al.
Publicado: (2022)